Overactive bladder or non-neurogenic overactive bladder is a syndrome characterized by urinary urgency, frequency, nocturia and urgency incontinence.
It is not a disease but a symptom complex that generally is not a life-threatening condition. It is also known as bladder spasms.
Urgency is the complaint of sudden, compelling desire to pass urine that is difficult to deny. It is considered a hallmark symptom of overactive bladder.
Frequency is usually micturition of >7 episodes during waking hours.
Nocturia is the interruption of sleep one or more times because of the need to void.
Urgency incontinence is the involuntary leakage of urine associated with a sudden compelling desire to void.
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.
Selective bladder denervation provides a minimally invasive treatment option for female patients with refractory overactive bladder (OAB), with data from two prospective feasibility studies showing that the intervention improves symptoms over 6 months of follow-up.
A 12-month treatment course with the combination of mirabegron plus solifenacin is safe and effective in patients with overactive bladder (OAB), reducing the number of incontinence episodes and micturition without unexpected toxicities, according to the results of the phase III SYNERGY II study.
There appears to be a substantial percentage of overactive bladder (OAB) patients who have sleep disturbance and fatigue, which are in turn associated with more severe urinary incontinence (UI)/OAB symptoms, worse health-related quality of life and poorer psychosocial health, a study has found.
Older patients with overactive bladder (OAB) appear to have increased frailty compared with individuals seeking care for other nononcologic urologic diagnosis, with frailty being a significant predictor of OAB, a study has found.
In patients with nocturnal urgency secondary to overactive bladder (OAB) and low nocturnal bladder capacity, a mismatch between nocturnal urine production and bladder capacity may predict response to treatment with fesoterodine, according to a study. Symptom improvement appears to be mediated by increases in typical rather than maximum nocturnal voided volumes and be associated with improved quality of life.
Large post-void residual (PVR) volume following onabotulinumtoxin A injection in patients with overactive bladder syndrome (OAB) appear to be associated with low voiding efficiency and low 3-day daytime frequency episodes, a new study reports.
The implant of a tibial nerve stimulator device for overactive bladder (OAB) appears to yield significant improvements in symptoms and quality of life (QoL) without inducing walking disturbances or pain at the implant site, according to a study.
Urinary nerve growth factor/creatinine levels, aside from being a potential biomarker for paediatric overactive bladder (OAB), may also predict therapeutic efficacy in children with OAB, a study suggests.
Many patients prescribed antibiotics for suspected urinary tract infection (UTI) in the emergency department (ED) may not actually require them, according to a single-centre study from the UK presented at ECCMID 2019.
Homosexual men are more likely to suffer from erectile dysfunction than their heterosexual counterparts, according to a recent meta-analysis. On the other hand, the opposite is true for premature ejaculation.
Overprescription of opioids after pelvic floor surgery and a provider education intervention have led to a substantial decrease in opioid prescribing without changing patient satisfaction with pain control, a recent study has found.